Magyar Dermatológiai Társulat On-line

Psoriasis arthritis new therapy, Klinikai vizsgálat a Psoriatic Arthritis: Rituximab - Klinikai vizsgálatok nyilvántartása - ICH GCP


    Beavatkozás neve: Rituximab Leírás: mg 1gm given as an IV infusion every two weeks for 2 doses days 1 and Exclusion Criteria: - History of malignancy other than resolved squamous or basal cell or cervical carcinoma - Presence of a significant medical illness that, in the opinion of the investigator, would potentially compromise the subject's ability to participate in the trial - Presence of another rheumatic or skin disease that, in the opinion of psoriasis arthritis new therapy investigator, could confound the ability to discern response - History or presence of HIV - History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies - History of recurrent significant infection or history of recurrent bacterial infections - Known active bacterial, viral, fungal, mycobacterial, or other infection including tuberculosis or atypical mycobacterial disease, but excluding fungal infections of nail beds or any major episode of infection requiring hospitalization or treatment with i.

    vörös foltok a tenyéren viszkető fotó

    Topical medications to treat psoriasis are limited to class VI and VII low potency steroids to the palms, soles of the feet, axilla and groin only.